Novo Nordisk A/S (NVO) · Deep analysis

Report previewNVO.USReport date Last updated
← Back to reports
Report contents
01

Business model

Business model: one molecule family carries the P&L

What Novo sells, and who actually pays

Novo Nordisk is a branded pharmaceutical manufacturer. It discovers, tests, produces and sells peptide drugs that mimic gut and pancreatic hormones, and it books revenue when wholesalers and distributors take delivery. The commercial core is semaglutide, sold under several brand names, and the two end markets are type 2 diabetes and chronic weight management. Patients inject or swallow the drug, physicians prescribe it, and third parties settle most of the bill: commercial insurers and Medicare in the U.S., national health services in Europe and Asia. The customer that constrains the business is the payer, not the patient.

BrandMolecule and formPrimary useWho pays
Ozempicsemaglutide, weekly injectionType 2 diabetesCommercial plans, Medicare Part D, national systems
Rybelsusoral semaglutideType 2 diabetesSame
Wegovysemaglutide, weekly injectionObesity, cardiovascular risk reductionEmployers, commercial plans, some national systems
Victoza, SaxendaliraglutideDiabetes, obesityFacing generic entry

Novo reports by therapy area and by geography. The U.S. is the largest single market and the one where realized price is set through rebates and formulary placement, not through a published list price. That single fact shapes everything else about the business.

Manufacturing scale against payer power

Novo has kept more of the supply chain inside the company than most branded-drug makers. It makes semaglutide itself and has spent heavily on fill-finish capacity, which is why supply, not demand, was the binding constraint on growth during the shortage years. One molecule covering four brands spreads fixed costs across a very large volume base, and that is where the gross margin comes from. The concentration is symmetrical: the same molecule is nearly the whole franchise, so anything that touches semaglutide pricing or exclusivity touches almost the entire income statement.

Bargaining power has moved toward payers. Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity) gives formulary committees a substitute that showed greater average weight loss in head-to-head trials. The U.S. Medicare drug price negotiation program selected semaglutide, with negotiated prices taking effect in 2027. Novo can defend volume through clinical data, reliable supply, outcomes labels and contracting, but it cannot simply raise price. Once the FDA declared the semaglutide shortage resolved and much of the compounded copycat market closed, volume moved back to the brands. The episode also showed how much of the cash-paying end of the U.S. market is price-sensitive, which matters for how far the company can push direct-to-patient pricing before it undermines insured reimbursement.

The 2030 test: a second engine or a longer runway

At its Capital Markets Day on September 21, 2026, Chief Executive Maziar Mike Doustdar built the strategy on three commitments: sustainable growth, a broader pipeline and attractive returns. The materials cite more than 550 million people with diabetes and more than 900 million with obesity, drawing on the International Diabetes Federation's Diabetes Atlas and the World Obesity Atlas. Demand is not the constraint. Time is. Semaglutide exclusivity ends in different markets on different schedules, and the next increment has to come from an oral obesity formulation, the cagrilintide-semaglutide combination, label expansions into cardiovascular, kidney and liver disease, and non-incretin areas such as hemophilia.

That is where the real tradeoff sits. Wider labels increase the number of patients a payer must cover and make the drug harder to fence off with prior authorization. They also require outcomes trials and plant capacity years before revenue arrives, and no payer pays a premium for a molecule it already covers simply because the label grew. If the pipeline mostly switches existing patients to new formats, Novo absorbs the cost of diversification without buying much growth.

What would overturn the read

The judgment that matters most: Novo's economics are payer-set and single-molecule, so the durability question is about calendar time, not about demand. Two observations would break that. If U.S. obesity volume keeps compounding while realized price per prescription falls only modestly after 2027, the franchise is far more elastic than its concentration implies. If oral semaglutide and CagriSema instead launch mainly by switching existing patients, revenue grows while the second engine does not exist. The evidence so far does not settle either.

Questions worth following

  • Can Novo Nordisk hold U.S. obesity share against tirzepatide?

    Obesity is the growth engine and the U.S. is its most profitable market. If tirzepatide keeps taking share, Novo must buy volume with rebates, which lowers realized price even as prescription counts rise. Franchise share is the cleanest read on whether clinical data still commands a premium.

  • Can Novo defend US semaglutide net price past 2027?

    Realized US price decides whether obesity volume growth converts into profit. Sales growth of 4% at constant exchange rates, against much faster obesity volume gains, implies price and mix already dilute the top line; a further step-down would reach operating profit almost intact.

  • Can Novo's next-generation pipeline replace semaglutide revenue?

    Semaglutide's exclusivity runs out within the decade, so the 2030 ambition depends on CagriSema, zenagamtide and the oral amylin reaching patients before then. If those assets arrive late or prove undifferentiated, revenue and the terminal growth assumption behind the valuation both fall.

02

Financial quality

Financial quality: strong returns, thinner margins

Novo Nordisk still earns returns most drug manufacturers cannot approach, and its earnings arrive as cash. What has changed since 2023 is the direction of margins and the scale of the manufacturing build. Leverage is not the constraint; the return on the capital now going into plants is the open question.

Returns: exceptional, with a rising equity denominator

ROE fell from 88.1% in FY2023 to 60.7% in FY2025. Net income rose 22% over that stretch (DKK 83.7bn to DKK 102.4bn) while equity rose 82% (DKK 106.6bn to DKK 194.1bn), so the decline reflects a larger capital base, not weaker profitability. Debt funded part of that growth: total liabilities rose from DKK 207.9bn to DKK 348.9bn, mostly DKK 118.9bn of long-term borrowings. Even so, net debt of about DKK 105bn at December 2025 was 0.67x EBITDA, and roughly DKK 90bn (about 0.5x) at September 2026. An estimate built from reported figures puts FY2025 ROIC near 35%, against roughly 45% in FY2024 and above 70% in FY2023, when invested capital was unusually thin. Even the current level sits well above any plausible cost of capital.

Margins: price is now the pressure point

Gross margin has fallen 7.6 percentage points from FY2023's 84.6% to 77.0% in the September 2026 quarter, and net margin from 36.0% to 21.1%. Two forces are at work. The company said in its November 4 announcement that the quarter carried DKK 8.7bn of non-cash impairments on ziltivekimab, a heart drug that missed its trial goals, and on part of the manufacturing network; adjusted operating profit still rose 27% at constant exchange rates. The more durable pressure is price. Novo plans to cut Wegovy's U.S. list price by about 50% and Ozempic's by 35% starting January 1, 2027, betting that volume compensates. That changes the revenue mix structurally, and it makes the 2027 gross margin the number to watch.

Cash and capital: conversion holds, free cash flow does not

Operating cash flow covered net income in every year shown (1.16x to 1.42x), so these are cash earnings. In the September 2026 quarter the ratio reached 2.46x, flattered by the impairment add-back. Free cash flow is the weaker series: DKK 70.0bn in FY2023 and DKK 69.7bn in FY2024, then DKK 29.0bn in FY2025 as capex jumped to DKK 90.1bn, or 29% of revenue. Net PP&E has climbed from DKK 162.5bn to DKK 240.8bn in seven quarters, and asset turnover has fallen from 0.84 to 0.61 since FY2023. The build pays off only if oral Wegovy and CagriSema fill it; if U.S. price cuts land first, the same asset base earns less per krone of revenue and ROIC keeps sliding.

Liquidity and what to check

The current ratio has sat between 0.74 and 0.89 for five years and the quick ratio between 0.55 and 0.69. For a business generating DKK 119bn of operating cash flow against DKK 118bn of long-term debt, that reads as a funding choice rather than distress, though it leaves little slack if refinancing conditions tighten.

Three items deserve checking. Net receivables rose from DKK 75.7bn at December 2025 to DKK 99.0bn at September 2026, up 31% while nine-month revenue grew about 11%, lifting receivable days from roughly 89 to 114; rebate accruals and U.S. channel mix may explain it, and the annual filing should separate them. Second, nine-month free cash flow of about DKK 82.5bn already exceeds the DKK 60–70bn full-year guidance management gave on November 4, implying a Q4 outflow of DKK 14–24bn; back-loaded capex would explain it. Third, the March 2026 quarter stands apart: revenue of DKK 96.8bn, 24% above the prior-year quarter, and a 50.2% net margin, against full-year guidance of roughly flat sales at constant currencies. Novo's disclosures do not identify the item behind that quarter, and it should not be annualized. Goodwill of DKK 19.4bn, after a manufacturing network writedown, is the other balance to test for further impairment.

Financial quality: Strong. Returns and cash conversion remain excellent and leverage is light; margin durability under the 2027 price cuts and the payoff from DKK 90bn of annual capex are the parts still unproven.

Table 1: annual core metrics
DKK bn or %FY2021FY2022FY2023FY2024FY2025Q3 2026Assessment
Revenue140.8177.0232.3290.4309.179.2Strong
Gross margin83.283.984.684.781.077.0Weak, declining
Operating margin41.642.344.244.241.329.1Weak
Net margin33.931.436.034.833.121.1Adequate
ROE71.272.088.180.860.7n/mExceptional
ROIC (est.)5659724535n/mExceptional
Liabilities/assets12.09.27.120.924.122.4Strong
Net debt/EBITDA (x, est.)0.190.120.070.550.67~0.5Strong
Current ratio0.860.890.820.740.800.84Adequate
Operating cash flow55.078.9108.9121.0119.141.2Strong
Capex (est.)7.414.838.951.390.113.1Weak, heavy
Free cash flow47.664.170.069.729.028.1Adequate
OCF/net income (x)1.151.421.301.201.162.46Strong
Capex/revenue5.28.316.717.729.216.6Weak
Asset turnover0.830.810.840.740.61n/mWeak

*Single quarter, July–September 2026; flows are not comparable with annual figures. Capex derived as operating cash flow minus free cash flow. ROIC uses EBIT taxed at roughly 21–25% over equity plus debt less cash.

Table 2: quarterly metrics
DKK bn, single quarterRevNet inc.Total assetsLiabilitiesNet PP&EOCFFCFNet margin %AssessmentTrend
Q1 202578.129.0489.2350.6172.424.610.037.2StrongBaseline
Q2 202576.926.5482.2314.1180.840.824.534.5StrongStable
Q3 202575.020.0512.3342.4193.246.130.726.7AdequateSoftening
Q4 202579.126.9542.9348.9208.47.6-36.234.0Adequate; cash outflowDeteriorating
Q1 202696.848.6559.2356.2220.024.112.050.2Outlier, unexplainedAnomalous
Q2 202678.521.0594.9373.7231.855.242.426.7AdequateRecovering cash
Q3 202679.216.7599.2381.4240.841.228.121.1Weak margins, strong cashMixed

Questions worth following

  • Can Novo keep gross margin above 75% after U.S. price cuts?

    Gross margin has already fallen from 84.6% to 77.0%, and Wegovy's U.S. list price drops roughly 50% in January 2027 with Ozempic down 35%. Whether volume and mix absorb that determines if the exceptional returns on capital survive.

  • Will Novo's manufacturing build lift asset turnover by 2028?

    Capex reached 29% of revenue in FY2025 and net PP&E has grown by nearly half in seven quarters, while asset turnover fell from 0.84 to 0.61. Whether new capacity is used decides if ROIC stabilizes near 35% or keeps eroding.

  • Will Novo's cash conversion hold as rebates and receivables build?

    Operating cash flow has covered net income at 1.16x to 1.42x, but receivables rose 31% in nine months against roughly 11% revenue growth. If that gap persists, reported profit outruns collections and free cash flow depends more on financing.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Novo Nordisk A/S